Hepatocellular carcinoma

肝细胞癌 索拉非尼 医学 癌症 催眠药 肝移植 乙型肝炎病毒 肿瘤科 内科学 疾病 肝癌 移植 免疫学 病毒
作者
Josep Maria Llovet,Jessica Zucman‐Rossi,Eli Pikarsky,Bruno Sangro,M. Schwartz,Morris Sherman,Gregory James Gores
出处
期刊:Nature Reviews Disease Primers [Nature Portfolio]
卷期号:2 (1): 16018-16018 被引量:2650
标识
DOI:10.1038/nrdp.2016.18
摘要

Liver cancer is the second leading cause of cancer-related deaths globally and has an incidence of approximately 850,000 new cases per year. Hepatocellular carcinoma (HCC) represents approximately 90% of all cases of primary liver cancer. The main risk factors for developing HCC are well known and include hepatitis B and C virus infection, alcohol intake and ingestion of the fungal metabolite aflatoxin B1. Additional risk factors such as non-alcoholic steatohepatitis are also emerging. Advances in the understanding of the molecular pathogenesis of HCC have led to identification of critical driver mutations; however, the most prevalent of these are not yet druggable targets. The molecular classification of HCC is not established, and the Barcelona Clinic Liver Cancer staging classification is the main clinical algorithm for the stratification of patients according to prognosis and treatment allocation. Surveillance programmes enable the detection of early-stage tumours that are amenable to curative therapies — resection, liver transplantation or local ablation. At more developed stages, only chemoembolization (for intermediate HCC) and sorafenib (for advanced HCC) have shown survival benefits. There are major unmet needs in HCC management that might be addressed through the discovery of new therapies and their combinations for use in the adjuvant setting and for intermediate- and advanced-stage disease. Moreover, biomarkers for therapy stratification, patient-tailored strategies targeting driver mutations and/or activating signalling cascades, and validated measurements of quality of life are needed. Recent failures in the testing of systemic drugs for intermediate and advanced stages have indicated a need to refine trial designs and to define novel approaches. Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and has well-known risk factors, including cirrhosis and viral hepatitis. Here, Llovet and colleagues discuss the challenges and recent advances in HCC molecular characterization, diagnosis and management.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
执着的尔容完成签到,获得积分10
1秒前
ding的应助被炙热晋鹏采纳,获得10
1秒前
1秒前
1秒前
2秒前
3秒前
3秒前
3秒前
liyuna0910发布了新的文献求助10
3秒前
5秒前
露露发布了新的文献求助10
5秒前
斯文败类的应助被刘一一采纳,获得10
6秒前
酷波er的应助被虞山小王子采纳,获得10
7秒前
若安在完成签到,获得积分10
7秒前
豆咕噜发布了新的文献求助10
8秒前
mengjie发布了新的文献求助10
8秒前
8秒前
8秒前
fx发布了新的文献求助10
8秒前
秋风的应助被qin202569采纳,获得10
8秒前
Miracle_wh完成签到 ,获得积分10
9秒前
moya完成签到,获得积分10
9秒前
9秒前
脑洞疼的应助被lilili采纳,获得10
10秒前
10秒前
11秒前
xgx984完成签到,获得积分10
12秒前
hchen发布了新的文献求助10
12秒前
Zoe发布了新的文献求助10
13秒前
炙热晋鹏发布了新的文献求助10
13秒前
13秒前
14秒前
烟花的应助被江河湖海采纳,获得10
16秒前
zombie发布了新的文献求助10
17秒前
顾矜的应助被mmm采纳,获得10
18秒前
英俊的铭的应助被李盛男采纳,获得10
18秒前
dxftx发布了新的文献求助10
19秒前
20秒前
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184462
求助须知:如何正确求助?哪些是违规求助? 9573447
关于积分的说明 21831674
捐赠科研通 7781651
什么是DOI,文献DOI怎么找? 3434363
关于科研通互助平台的介绍 2558468
邀请新用户注册赠送积分活动 2480923